Corient Private Wealth LP Has $3.34 Million Stock Holdings in Medpace Holdings, Inc. $MEDP

Key Points

• Corient Private Wealth increased its Medpace stake by 291.4% in the second quarter, bringing its holdings to 6,314 shares worth approximately $3.34 million. Institutional investors collectively own 77.98% of the company.
• Medpace reported stronger-than-expected quarterly results, with EPS of $4.25 and revenue of $707.33 million, up 17.2% year over year. The company issued fiscal 2026 EPS guidance of $17.25 to $17.95.
• Medpace shares opened at $612.33, while analysts maintain a consensus “Hold” rating and an average price target of $595.20. Insiders sold approximately $97.5 million worth of stock over the past three months.

Corient Private Wealth LP boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 291.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,314 shares of the company's stock after purchasing an additional 4,701 shares during the quarter. Corient Private Wealth LP's holdings in Medpace were worth $3,344,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. American Capital Management Inc. acquired a new position in shares of Medpace in the second quarter valued at approximately $111,329,000. Focus Partners Advisor Solutions LLC acquired a new stake in Medpace during the 2nd quarter worth approximately $1,685,000. California State Teachers Retirement System boosted its stake in Medpace by 22.1% in the 1st quarter. California State Teachers Retirement System now owns 26,042 shares of the company's stock valued at $12,505,000 after purchasing an additional 4,719 shares during the period. BlackRock Inc. bought a new stake in Medpace in the 2nd quarter valued at $1,323,047,000. Finally, Madison Asset Management LLC acquired a new position in Medpace in the 2nd quarter valued at $128,956,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Medpace news, Director Robert O. Kraft sold 3,858 shares of Medpace stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $617.81, for a total value of $2,383,510.98. Following the transaction, the director owned 955 shares in the company, valued at $590,008.55. The trade was a 80.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Kevin M. Brady sold 3,400 shares of the business's stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $625.24, for a total value of $2,125,816.00. Following the transaction, the chief financial officer directly owned 12,830 shares of the company's stock, valued at approximately $8,021,829.20. The trade was a 20.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 159,212 shares of company stock worth $97,515,460 over the last three months. Insiders own 20.50% of the company's stock.

Medpace Price Performance

Medpace stock opened at $612.33 on Monday. The firm has a market cap of $17.09 billion, a PE ratio of 35.89, a price-to-earnings-growth ratio of 2.73 and a beta of 1.15. The stock's fifty day moving average price is $585.86 and its two-hundred day moving average price is $510.89. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. During the same quarter in the prior year, the business posted $3.10 earnings per share. Medpace's revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Leerink Partners set a $620.00 target price on Medpace in a report on Thursday, July 23rd. Weiss Ratings upgraded shares of Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 12th. Jefferies Financial Group reaffirmed a "hold" rating on shares of Medpace in a research report on Monday, September 14th. Mizuho lifted their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. Finally, BMO Capital Markets boosted their price objective on shares of Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, Medpace has a consensus rating of "Hold" and a consensus price target of $595.20.

About Medpace

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.